28.07.2015Publication: Improving Treatment for Rectal Cancer

Professor Torsten Hothorn of the EBPI served as responsible biostatistician and committee member on a long-running randomized trial that reported its results recently in The Lancet Oncology. The trial, funded by German Cancer Aid, examined whether the addition of the drug oxaliplatin to the usual treatment with chemotherapy (fluorourcil) and radiotherapy increases time spent in remission for patients with advanced rectal cancer. The trial showed that patients did indeed benefit from the new treatment therapy. Professor Torsten Hothorn of the EBPI contributed to study design, randomization, data collection, and statistical analyses. For more, see: The Lancet